Humacyte, Inc. (NASDAQ:HUMA) Stock Has Average Price Target of $4.48 According to Analysts

Humacyte logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is moderately positive: Six of eight analysts rate Humacyte a buy, while one rates it hold and one sell. The average 12-month price target is $4.48.
  • HUMA opened at $0.50, near its 52-week low of $0.34 and below its 52-week high of $1.52; its 50-day and 200-day moving averages were $0.49 and $0.77, respectively.
  • Institutional investors and hedge funds own 44.71% of Humacyte’s shares. The biotech’s lead product, Symvess, an engineered vessel for certain arterial injuries, was approved by the FDA in December 2024.
  • Five stocks to consider instead of Humacyte.

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $4.48.

HUMA has been the topic of a number of research analyst reports. Barclays lifted their target price on Humacyte from $0.50 to $0.60 and gave the company an "equal weight" rating in a research report on Wednesday, November 11th. Williams Trading set a $1.00 price objective on shares of Humacyte in a report on Friday, October 16th. BTIG Research reaffirmed a "buy" rating and issued a $2.00 target price on shares of Humacyte in a research report on Tuesday, November 10th. Wall Street Zen upgraded shares of Humacyte to a "sell" rating in a research report on Saturday, November 14th. Finally, HC Wainwright reissued a "buy" rating on shares of Humacyte in a research note on Friday, October 16th.

Check Out Our Latest Stock Analysis on HUMA

Institutional Trading of Humacyte

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HUMA. Alyeska Investment Group L.P. purchased a new position in shares of Humacyte during the second quarter worth $4,700,000. BlackRock Inc. purchased a new stake in shares of Humacyte in the 2nd quarter valued at $3,777,000. Marshall Wace LLP lifted its stake in Humacyte by 1,548.0% during the 3rd quarter. Marshall Wace LLP now owns 2,996,553 shares of the company's stock worth $1,558,000 after acquiring an additional 2,814,722 shares in the last quarter. GSA Capital Partners LLP acquired a new position in Humacyte during the 2nd quarter worth about $785,000. Finally, Private Advisor Group LLC acquired a new position in Humacyte during the 3rd quarter worth about $491,000. Hedge funds and other institutional investors own 44.71% of the company's stock.

Humacyte Stock Down 0.2%

HUMA stock opened at $0.50 on Thursday. Humacyte has a one year low of $0.34 and a one year high of $1.52. The firm has a market cap of $138.90 million, a PE ratio of -1.14 and a beta of 2.64. The firm's 50 day moving average price is $0.49 and its 200-day moving average price is $0.77. The company has a debt-to-equity ratio of 3.65, a quick ratio of 3.11 and a current ratio of 3.34.

About Humacyte

(Get Free Report)

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company's lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient's own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.

Featured Stories

Analyst Recommendations for Humacyte (NASDAQ:HUMA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Humacyte Right Now?

Before you consider Humacyte, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.

While Humacyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines